Viatris Inc. announced that the FDA has approved Gwyn Lo (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo is a new combined hormonal contraceptive patch with low-dose estrogen…. read more.
The European Medicines Agency (EMA) has unveiled a series of initiatives designed to address low representation of women in clinical trials and gaps in understanding sex-based differences in… read more.
While more women globally are using medication to have abortions, a University of Maryland-led study out today in JAMA Psychiatry found no evidence that a first medication or procedural abortion… read more.
Emergency Medicine & Intensive Care
Forty per cent of women with ovarian cancer only receive a diagnosis after an emergency hospital admission, a new study reports. Ovarian cancer detected following an emergency admission is more likely to be at an advanced stage, with… read more.
There has been a lot of discussion about how the age at menopause can affect menopause symptoms. A new study compared the prevalence and severity of menopause symptoms… read more.
Organon announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA, a hormone-free, copper intrauterine device (IUD). Please see our prior… read more.
Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome… read more.
A new study from Michigan State University found increases in binge eating when taking hormone pills in the form of oral contraceptives — but not in all women…. read more.
A target trial emulation estimated the risks associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure in early pregnancy. The findings did not indicate substantially increased risk for nonlive… read more.
Eli Lilly and Company, the maker of Zepbound (tirzepatide), announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced significant weight… read more.
National Institute for Health and Care (NICE) has recommended mirvetuximab soravtansine (Elahere; AbbVie) for NHS use, marking the first new targeted therapy for platinum-resistant ovarian cancer in over… read more.
Researchers at UBC found that B.C.’s decision to provide universal, no-cost prescription contraception sharply reduced what patients pay, with the largest financial gains for people in their 20s…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
